Form 4: Celldex Therapeutics Director Rita Jain Acquires Stock Options

Director Rita Jain acquired 16,500 non-qualified stock options in Celldex Therapeutics on June 13, 2024.

Summary

• Rita Jain, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• The options vest on June 13, 2025, and expire on June 13, 2034.
• Following the transaction, Ms. Jain directly owns 16,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of stock options granted to a director, which is a common practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard practice for compensating and incentivizing board members in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their director compensation packages.
• The size and terms of the grant are generally in line with industry standards for companies of similar size and stage of development.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates